Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Daniela Di, Pinto"'
Autor:
Francesca Rossi, Chiara Tortora, Martina Di Martino, Alessandra Di Paola, Daniela Di Pinto, Maria Maddalena Marrapodi, Maura Argenziano, Elvira Pota
Publikováno v:
PLoS ONE, Vol 17, Iss 7, p e0271730 (2022)
Childhood cancer survivors (CCS) are predisposed to the onset of osteoporosis (OP). It is known that iron overload induces osteoclasts (OCs) overactivity and that the iron chelator Deferasirox (DFX) can counteract it. The Cannabinoid Receptor type 2
Externí odkaz:
https://doaj.org/article/9ab5297887194275a4ecb6d2e056c30e
Autor:
Vincenzo Piccolo, Teresa Russo, Daniela Di Pinto, Elvira Pota, Martina Di Martino, Giulio Piluso, Andrea Ronchi, Giuseppe Argenziano, Eugenia Veronica Di Brizzi, Claudia Santoro
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Poikiloderma with neutropenia (PN) is a very rare genetic disorder mainly characterized by poikiloderma and congenital neutropenia, which explains the recurrence of respiratory infections and risk of developing bronchiectasis. Patients are also prone
Externí odkaz:
https://doaj.org/article/2e6607f7dba045f2a61e22fd3c086ff0
Autor:
Annamaria Mascolo, Cristina Scavone, Michele Bertini, Simona Brusco, Francesca Punzo, Elvira Pota, Martina Di Martino, Daniela Di Pinto, Francesca Rossi
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundAmong factors influencing the higher risk of developing unknown or rare adverse drug reactions (ADRs) among children and adolescents, there is the frequent off-label use of drugs that seems to be very common in pediatric oncological patient
Externí odkaz:
https://doaj.org/article/4b71959d2df6403a922460acdd8ef75a
Autor:
Maura Argenziano, Chiara Tortora, Elvira Pota, Alessandra Di Paola, Martina Di Martino, Caterina Di Leva, Daniela Di Pinto, Francesca Rossi
Publikováno v:
Pharmaceuticals, Vol 14, Iss 9, p 923 (2021)
Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity, chemoresistance and its interaction with bone microenvironment. The 5-year
Externí odkaz:
https://doaj.org/article/78f0bb1d10f54b3a9c0433950b13b2d0
Autor:
Daniela Di Pinto, Alessandra Di Paola, Chiara Tortora, Maura Argenziano, Silverio Perrotta, Martina Di Martino, Elvira Pota, Francesca Rossi, Francesca Punzo
Publikováno v:
Current Cancer Drug Targets. 21:443-455
Background: Osteosarcoma is an aggressive bone tumor. Itrepresents the principal cause of cancer-associated death in children.Considering the recent findings on the role of iron in cancer, iron chelation has been investigated for its antineoplastic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87b8275bdaefd4067a93d1b96b78fdb
https://doi.org/10.2174/1568009620666201230090531
https://doi.org/10.2174/1568009620666201230090531
Autor:
Ilaria Riccio, Elvira Pota, Marco Marcarelli, Maria Carmen Affinita, Daniela Di Pinto, Cristiana Indolfi, Nicola Del Regno, Marco Esposito
Publikováno v:
La Pediatria Medica e Chirurgica, Vol 38, Iss 3 (2016)
Osteonecrosis is a significant adverse effect of treatment administered to children suffering from acute lymphoblastic leukemia (ALL) that may have a negative effect on the quality of life. The purpose of this study is to evaluate the rate of seconda
Externí odkaz:
https://doaj.org/article/c2e90cc9b8614ec98a9691684f50764c
Autor:
Alessandra Di Paola, Elvira Pota, Francesca Punzo, Chiara Tortora, Daniela Di Pinto, Francesca Rossi, Maura Argenziano, Martina Di Martino
Publikováno v:
Oncotarget
Osteosarcoma is an aggressive bone tumor of the pediatric age. It is therefore important to improve conventional therapies (chemotherapy and surgery). Anticancer drugs often cause osteoporosis due to a misbalance of RANK/RANK-L/OPG pathway. Denosumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::484d3b5558467a57ba675a1dc123beb5
https://doi.org/10.18632/oncotarget.27669
https://doi.org/10.18632/oncotarget.27669
Autor:
Francesca Punzo, Maura Argenziano, Chiara Tortora, Alessandra Di Paola, Margherita Mutarelli, Elvira Pota, Martina Di Martino, Daniela Di Pinto, Maria Maddalena Marrapodi, Domenico Roberti, Francesca Rossi
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 15; Pages: 8651
Acute lymphoblastic leukemia type B (B-ALL) is the most common kind of pediatric leukemia, characterized by the clonal proliferation of type B lymphoid stem cells. Important progress in ALL treatments led to improvements in long-term survival; nevert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bf725245995ea97d41996656790623
http://hdl.handle.net/11591/475848
http://hdl.handle.net/11591/475848
Autor:
Francesca Rossi, Chiara Tortora, Marco Paoletta, Maria Maddalena Marrapodi, Maura Argenziano, Alessandra Di Paola, Elvira Pota, Daniela Di Pinto, Martina Di Martino, Giovanni Iolascon
Publikováno v:
Cancers. 14:4349
The improvement of chemotherapy, radiotherapy, and surgical interventions, together with hematopoietic stem cell transplantation, increased childhood cancer survival rate in the last decades, reaching 80% in Europe. Nevertheless, anti-cancer treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b52ba94474c44ad2220df4f6a8123a1
https://doi.org/10.3390/cancers14184349
https://doi.org/10.3390/cancers14184349
Autor:
Simona Brusco, Annamaria Mascolo, Elvira Pota, Francesca Punzo, Francesca Rossi, Daniela Di Pinto, Cristina Scavone, Martina Di Martino, Michele Bertini
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology, Vol 11 (2020)
Background Among factors influencing the higher risk of developing unknown or rare adverse drug reactions (ADRs) among children and adolescents, there is the frequent off-label use of drugs that seems to be very common in pediatric oncological patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1783bda55b9ce3ce198577eb96d6a812
http://europepmc.org/articles/PMC7221123
http://europepmc.org/articles/PMC7221123